bioAffinity Technologies (BIAF) Accumulated Expenses (2021 - 2026)

bioAffinity Technologies (BIAF) has reported Accumulated Expenses for 6 consecutive years, with $2.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 118.18% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $2.0 million (up 118.18% YoY), while the FY2025 annual figure was $1.3 million, down 6.36% from the prior year.
• Accumulated Expenses advanced to $2.0 million in Q1 2026 per BIAF's latest filing, from $1.3 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $2.0 million in Q1 2026 and bottomed at $276519.0 in Q2 2023.
• Historically, Accumulated Expenses has averaged $948387.0 across 5 years, with a median of $883319.0 in 2024.
• Annual changes were most pronounced in 2023 — Accumulated Expenses sank 59.76% — and 2024, when it soared 214.25%.
• bioAffinity Technologies' Accumulated Expenses stood at $541894.0 in 2022, then soared by 112.18% to $1.1 million in 2023, then increased by 21.65% to $1.4 million in 2024, then fell by 6.36% to $1.3 million in 2025, then surged by 55.29% to $2.0 million in 2026.
• Business Quant data shows BIAF's Accumulated Expenses at $2.0 million in Q1 2026, $1.3 million in Q4 2025, and $717762.0 in Q3 2025.